PremiumCompany AnnouncementsBrightSpring Shareholders Back Board, Auditor and Pay Practices23h ago8KBTSG
PremiumRatingsGlaukos: Buy Rating Reiterated as Favorable iDose LCD Eases Reimbursement Overhang and Sets Stage for Epioxa-Driven Growth1d agoGKOS
Glaukos: Buy Rating Reiterated as Favorable iDose LCD Eases Reimbursement Overhang and Sets Stage for Epioxa-Driven Growth
PremiumRatingsBrightSpring: Durable Above-Peer Growth Outlook Drives Price Target Increase to $70 and Reiterated Buy Rating1d agoBTSG
BrightSpring: Durable Above-Peer Growth Outlook Drives Price Target Increase to $70 and Reiterated Buy Rating